Literature DB >> 19057268

11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.

Hiroaki Nomori1, Hidekatsu Shibata, Kimiichi Uno, Kenichi Iyama, Yumi Honda, Rumi Nakashima, Kazuya Sakaguchi, Tomoyuki Goya, Iwao Takanami, Kiyoshi Koizumi, Takashi Suzuki, Masahiro Kaji, Hirotoshi Horio.   

Abstract

OBJECTIVES: Although positron emission tomography (PET) using F-fluorodeoxy-glucose (FDG) frequently gives false-negative results for slow-growing tumors, C-acetate (AC)-PET has been reported to be able to detect them. To determine the usefulness of AC-PET for imaging non-small cell lung cancers (NSCLCs), the sensitivity and specificity were compared between the AC-PET and FDG-PET with a multicenter study.
MATERIALS AND METHODS: A total of 284 pulmonary lesions (227 NSCLCs and 57 benign lesions) were examined using both AC-PET and FDG-PET before surgery at seven Japanese institutes. The AC- or FDG-uptake in each lesion were quantitatively measured using the contrast ratio of the standard uptake value between the lesions and the contralateral lung.
RESULTS: The sensitivity of AC-PET for diagnosing NSCLC was 0.71, which was significantly higher than the value of 0.57 obtained by FDG-PET (p < 0.001). No significant difference in the specificity was seen between AC- and FDG-PET. For the 146 well-differentiated adenocarcinomas, the sensitivity of AC-PET was 0.62, which was significantly higher than the value of 0.37 obtained by FDG-PET (p < 0.001). Of the 51 moderately- or poorly-differentiated adenocarcinomas and 30 nonadenocarcinomas, there was no significant difference of sensitivity between AC- and FDG-PET.
CONCLUSIONS: AC-PET could be used in place of FDG-PET for imaging NSCLC, with higher sensitivity for well-differentiated adenocarcinoma compared with FDG-PET.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19057268     DOI: 10.1097/JTO.0b013e31818ddfdc

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

1.  Acetate dependence of tumors.

Authors:  Sarah A Comerford; Zhiguang Huang; Xinlin Du; Yun Wang; Ling Cai; Agnes K Witkiewicz; Holly Walters; Mohammed N Tantawy; Allie Fu; H Charles Manning; Jay D Horton; Robert E Hammer; Steven L McKnight; Benjamin P Tu
Journal:  Cell       Date:  2014-12-18       Impact factor: 41.582

2.  The clinical use of PET with (11)C-acetate.

Authors:  Ilaria Grassi; Cristina Nanni; Vincenzo Allegri; Joshua James Morigi; Gian Carlo Montini; Paolo Castellucci; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

3.  SPECT and PET imaging of meningiomas.

Authors:  Varvara Valotassiou; Anastasia Leondi; George Angelidis; Dimitrios Psimadas; Panagiotis Georgoulias
Journal:  ScientificWorldJournal       Date:  2012-05-01

4.  Correlation of quantified metabolic activity in nonsmall cell lung cancer with tumor size and tumor pathological characteristics.

Authors:  Mehrdad Bakhshayesh Karam; Abtin Doroudinia; Bahareh Behzadi; Payam Mehrian; Abbas Yousefi Koma
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

Review 5.  Targeting extracellular nutrient dependencies of cancer cells.

Authors:  Javier Garcia-Bermudez; Robert T Williams; Rohiverth Guarecuco; Kıvanç Birsoy
Journal:  Mol Metab       Date:  2019-11-23       Impact factor: 7.422

6.  11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.

Authors:  Miao Chen; Wenjia Zhu; Jianhua Du; Chen Yang; Bing Han; Daobin Zhou; Li Huo; Junling Zhuang
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

7.  In-house development of an optimized synthetic module for routine [11C]acetate production.

Authors:  Hwa Youn Jang; Seong Young Kwon; Ayoung Pyo; Min Goo Hur; Sang Wook Kim; Jeong-Hoon Park; Hee-Jung Kim; Seung Dae Yang; Sunwoo Lee; Dong-Yeon Kim; Jung-Joon Min
Journal:  Nucl Med Commun       Date:  2015-01       Impact factor: 1.690

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.